List view / Grid view
14 July 2015 | By Victoria White
The FDA has approved Iressa for the first-line treatment of patients with NSCLC whose tumours have EGFR exon 19 deletions or exon 21 substitution mutations...
10 July 2015 | By Victoria White
Lilly has issued a statement in response to the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee’s ongoing review of necitumumab...
6 July 2015 | By Victoria White
Results from the LUX-Lung 8 Trial demonstrate that afatinib resulted in superior progression-free survival and overall survival compared to erlotinib...
3 June 2015 | By Victoria White
Boehringer Ingelheim’s VARGATEF in combination with docetaxel has been recommended for use within the National Health Service (NHS) in England and Wales...
3 June 2015 | By Victoria White
AbbVie has announced findings from a Phase 2 study of a veliparib regimen in patients with non-small cell lung cancer (NSCLC) who are current smokers...
3 June 2015 | By Victoria White
The FDA has accepted for review the sBLA for Merck’s anti-PD-1 therapy, Keytruda, for the treatment of patients with advanced non-small cell lung cancer...
1 June 2015 | By Victoria White
AstraZeneca has announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of EGFRm advanced non-small cell lung cancer (NSCLC)...
22 May 2015 | By Victoria White
The CHMP has adopted a positive opinion recommending that nivolumab be granted approval for the treatment of NSCLC after prior chemotherapy in adults...
14 May 2015 | By Victoria White
Roche has announced interim results from a global, randomised Phase II study (POPLAR) of MPDL3280A in people with previously treated NSCLC...
14 May 2015 | By Victoria White
Results from two pivotal studies have shown that alectinib shrank tumours in people with advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC)...
8 May 2015 | By Victoria White
The European Commission has approved Novartis’ Zykadia to treat adult patients with ALK+ NSCLC previously treated with crizotinib...
22 April 2015 | By Victoria White
Pfizer’s XALKORI has received Breakthrough Therapy designation from the FDA for the potential treatment of patients with ROS1-positive NSCLC...
20 April 2015 | By Victoria White
The first patient has been dosed in a Phase 1 clinical trial of CM-24, a first-in-class immunomodulatory mAb for the treatment of various types of cancers...
20 April 2015 | By Victoria White
New data from a Phase 1b study evaluating KEYTRUDA, in naïve and previously-treated patients with advanced NSCLC was presented at AACR 2015...
17 April 2015 | By Victoria White
CheckMate -057, a Phase III study evaluating Opdivo in patients with advanced non-squamous non-small cell lung cancer (NSCLC), has stopped early...
